United Kingdom

People: Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

23 Aug 2019
Change (% chg)

$-0.74 (-5.78%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Best, Simon 

Prof. Simon Geoffrey Best is Interim Chief Executive Officer of the company, He was Independent Chairman of the Board of the Company. Prof. Best is a seasoned veteran of the global Lifescience Industry with experience, both as a Founder, Chief Executive Officer and Chairman or board member of entrepreneurial companies and as a Chairman or board member of major industry bodies and public sector institutions in the UK, USA, Europe, Asia and Latin America including the UK BioIndustry Association (BIA) and the US Biotechnology Industry Organization (BIO). He is also an experienced Angel, Venture Capital and Private Equity investor. In 1999, the World Economic Forum nominated him a Global Leader of Tomorrow and in 2000, a Technology Pioneer of the Year. In 1999, he was nominated as "Science and Technology Venturer of the Year" by the Financial Times. He was awarded the London Business School Alumni Achievement Prize in 2007. He holds an MBA from London Business School and an Honorary Doctorate and B.Mus from York University. In 2007, he was elected a Fellow of the Royal Society of Edinburgh. In 2008, he was awarded an OBE by Queen Elizabeth II and appointed a Visiting Professor of Medicine by the University of Edinburgh. On November 4, 2015, Prof. Best was elected to the board of Evofem Inc., a women's health company based in San Diego. From March 2010 to August 2015, Prof. Best was the Chairman of Edinburgh BioQuarter with responsibility for company formation and technology transfer for the University of Edinburgh. In September 2015, this entity was replaced by Sunergos Innovations Limited. Sunergos was reabsorbed by the University in February 2017 after which Prof. Best continued to serve as a Senior Advisor. Prof. Best held also the position of Chief Executive Officer at Aquapharm Biodiscovery Ltd. (a company in the sector of drug discovery) from May 2010 to November 2012.

Basic Compensation

Total Annual Compensation, CAD 192,924
Restricted Stock Award, CAD --
Long-Term Incentive Plans, CAD --
All Other, CAD 84,409
Fiscal Year Total, CAD 277,333

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Simon Best


Bruce Pritchard


John Moran


Patrick Sartore


Gary Bridger


Stefan Clulow

As Of  31 Dec 2017